Traws Pharma, Inc. (TRAW) financial statements and ratios from SEC XBRL: revenue $2.79M (TTM), net margin 328.7%, revenue growth 1134.5% YoY, P/E 0.1. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $2.79M |
| Net Margin | 328.7% |
| Revenue Growth (YoY) | 1134.5% |
| EPS Growth (YoY) | -102.4% |
| FCF Growth (YoY) | -37.9% |
| P/E Ratio | 0.1 |
| EV / EBITDA | 0.0 |
| Price / Book | 5.07 |
| Price / Sales | 1.05 |
| FCF Yield | -76.9% |
| Altman Z-Score | -89.58 (distress) |
| Sector P/E (Healthcare) | 21.7 |
TRAW overview · TRAW earnings · TRAW KPIs · TRAW investor relations · TRAW ownership · TRAW peers · TRAW filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.